New diseases are emerging every day. The drugs which were being used a decade ago are not as effective as they used to be back then. This scenario has given doctors a hard time as they try to come up with new ways to treat new diseases. Amicus Therapeutics is a biotechnology company that focuses on finding ways to fight rare and orphan illnesses through the use of therapies. The global company uses unique technology and medicine as well to help people suffering from devastating diseases such as Lysosomal Storage Disorders, skin disorders, and Pompe disease.
Amicus Therapeutics was founded in 2002 and has around five hundred employees. It has its headquarters in Cranbury, New Jersey. The company cares for the many patients suffering from rare diseases which have troubled doctors from other medical institutions and ensures that they get the best care possible. The specialists in the company come up with clinical programs and carry out inventive science to create a platform where these people with the rare disorders can seek medical attention and be treated.
The goal of Amicus Therapeutics is to make a difference that is meaningful in the lives of all those patients with these critical conditions (https://www.dialdish.com/amicus-therapeutics-fabry-disease/). Many patients who have received help from the company and recovered fully from the special conditions claim that they had suffered for a long time before hearing about Amicus Therapeutics. Many reports that they were almost giving up after searching for solutions from many hospitals and clinics without success. That is how important the company is; for many people, it is usually the last hope.
Before 2008, Amicus Therapeutics had only one site, which was located in New Jersey (AliveNewspaper). This was before the company opened another one in San Diego. The company has received financial support from many sources due to its good work including grants from the Michael J. Fox Foundation and Alzheimer’s Drug Discovery Foundation.
Today, Amicus Therapeutics continues to look for better ways to help patients under the leadership of John F. Crowley who is the CEO and chairman of the company. Patients with these rare disorders will continue to get the help they need from the medical specialists for many years to come.